Six years ago, Sanofi gave $125 million and promised over $1 billion in milestone payments to buzzy neuroscience startup ...

Three US life-sciences companies have so far exceeded or met their goals in initial public offerings Thursday, showing ...

John Maraganore, the former CEO of Alnylam Pharmaceuticals, launched City Therapeutics, a new startup with $135 million from ...

Three U.S. healthcare startups priced their initial public offerings (IPO) on Thursday, including Upstream Bio which raised ...

CAMP4 Therapeutics Corporation ("CAMP4") (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics ...

CAMP4 Therapeutics (NASDAQ:CAMP) priced its IPO of 6.82M shares at an initial public offering price of $11.00 per share. The gross proceeds are expected to be ~$75M. CAMP4’s common stock is expected ...

Upstream Bio has swollen its IPO to $255 million as the company joins CAMP4 Therapeutics this morning in becoming the latest ...

Boston-area biotechs Upstream Bio and CAMP4 Therapeutics are headed to the Nasdaq on Friday, the latest companies to IPO in ...

Cambridge’s Camp4 Therapeutics Inc. and Waltham’s Upstream Bio Inc. will both make their debuts on the public markets Friday.

Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of ...

Tejon Ranch Company (NYSE: TRC) announced today that it has signed a joint venture agreement with Dedeaux Properties to develop and lease an approximately 510,500-square-foot, state-of-the-art ...

CAMP4 Therapeutics, a biopharmaceutical firm backed by healthcare giant Kaiser Permanente raised $75 million on Thursday in its U.S. initial public offering.